Other News To Note
Friday, March 16, 2012
InterMune Inc., of Brisbane, Calif., said Germany's reimbursement body granted the additional benefit of Esbriet (pirfenidone) in adults for mild to moderate idiopathic pulmonary fibrosis, classifying the drug's additional benefit as Stage IV, or not quantifiable. That designation "takes the worst-case scenario off the table," noted Wells Fargo analyst Brian Abrahams, and positions the firm "reasonably for upcoming pricing negotiations." Esbriet won European approval a year ago. The company is conducting another pivotal trial for FDA approval.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.